Hi Onion,
I think the company is tremendously successful, having an approved product available in so many districts. This is certainly one ethical investment you are making. The ADAPT process is phenomenally advanced in its capacity to remove the characteristics and dna of its donor (bovine).
But long term success (as you put it) will come down to selling enough patches to not only cover expenses, but turn a profit. A profit which could justify its current market capitalization. I think you know where I stand on that part.
Ann: CardioCel gains special access in Singapore, page-21
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |